Verastem Oncology to Present Expanded VS-7375 Data Across Three Cancer Types — Verastem, Inc.

Event summary

Verastem Oncology will present initial efficacy and updated safety data for VS-7375 in pancreatic, lung, and colorectal cancers on October 14, 2026.
The data comes from the ongoing TARGET-D clinical development program, building on a June 2026 update.
VS-7375 is a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, targeting both active and inactive states of the protein.
The company has received FDA Fast Track Designation for VS-7375 in pancreatic and lung cancers.
Verastem holds development and commercialization rights to VS-7375 outside GenFleet’s markets in Greater China.

The big picture

Verastem Oncology's presentation of VS-7375 data comes at a time when KRAS inhibitors are gaining traction in oncology, with several competitors vying for market share. The company's focus on a dual ON/OFF inhibitor could differentiate it in a crowded field, but success will depend on demonstrating superior efficacy and safety profiles. The Fast Track Designation from the FDA underscores the unmet need in KRAS G12D-mutated cancers, particularly in pancreatic and lung cancer indications.

What we're watching

Clinical Efficacy: How the expanded efficacy data for VS-7375 across pancreatic, lung, and colorectal cancers will position it against competitors in the KRAS inhibitor space.
Regulatory Pathway: Whether the Fast Track Designation will accelerate VS-7375's approval process and potential market entry.
Commercial Strategy: The pace at which Verastem can secure partnerships or commercialization agreements for VS-7375 outside of Greater China.